The patent covers certain uses of satraplatin related to the treatment of a cancer or tumor resistant or refractory to a taxane, including docetaxel (Taxotere) and paclitaxel (Taxol). The term of the patent extends up to 2025.
Bernd Seizinger, CEO of GPC Biotech, said: “With an active filing for satraplatin under review in Europe, we believe this patent will be of particular commercial importance, should satraplatin be approved for hormone-refractory prostate cancer patients whose prior chemotherapy has failed.”